|
| 37980367 | Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). | Br J Cancer | 2024 |
| 36115772 | Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer. | Eur Urol | 2023 |
| 36952642 | Combining Poly(ADP)-Ribose Polymerase Inhibitors With Abiraterone in Castration-Resistant Prostate Cancer: Is Biomarker Testing Necessary? | J Clin Oncol | 2023 |
| 37087376 | PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. | Eur Urol | 2023 |
| 37285866 | Combining next-generation hormonal therapy with PARP inhibition in metastatic castration-resistant prostate cancer. | Lancet | 2023 |
| 37277275 | Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. | Eur Urol | 2023 |
| 36974724 | Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients. | J Urol | 2023 |
| 36795891 | Rucaparib or Physician's Choice in Metastatic Prostate Cancer. | N Engl J Med | 2023 |
| 36243543 | Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. | Eur Urol | 2023 |
| 36123219 | Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer. | Eur Urol | 2023 |
| 34667026 | Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. | Clin Cancer Res | 2022 |
| 35617398 | Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. | Science | 2022 |
| 35735442 | A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a <i>RAD51B Alteration</i>. | Curr Oncol | 2022 |
| 35705558 | Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. | Nat Commun | 2022 |
| 35440569 | AKT mutant allele-specific activation dictates pharmacologic sensitivities. | Nat Commun | 2022 |
| 35538298 | Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality. | Prostate | 2022 |
| 35670774 | The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer. | Clin Cancer Res | 2022 |
| 35641398 | First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature. | Eur Urol Oncol | 2022 |
| 35210863 | Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. | Cancer Manag Res | 2022 |
| 34863587 | Inherited TP53 Variants and Risk of Prostate Cancer. | Eur Urol | 2022 |
| 33389388 | Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers. | Invest New Drugs | 2021 |
| 33558422 | Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. | Clin Cancer Res | 2021 |
| 34598946 | Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. | Clin Cancer Res | 2021 |
| 34133209 | Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. | J Clin Oncol | 2021 |
| 34059130 | Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. | Genome Med | 2021 |
| 34145282 | Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. | Nat Commun | 2021 |
| 34145028 | BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. | Clin Cancer Res | 2021 |
| 33334906 | Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in <i>BRCA2</i>-altered Prostate Tumors. | Clin Cancer Res | 2021 |
| 32220301 | Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. | Cancer Cell | 2020 |
| 34258585 | Accelerating precision medicine in metastatic prostate cancer. | Nat Cancer | 2020 |
| 31876541 | Morphologic and Immunohistochemical Assessment of CDH1 Loss of Function Alterations in Prostatic Adenocarcinoma. | Am J Surg Pathol | 2020 |
| 32086346 | Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. | Clin Cancer Res | 2020 |
| 31796516 | Significance of <i>BRCA2</i> and <i>RB1</i> Co-loss in Aggressive Prostate Cancer Progression. | Clin Cancer Res | 2020 |
| 32094488 | Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2020 |
| 32856010 | Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. | JCO Precis Oncol | 2020 |
| 32795228 | Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene Alteration. | J Clin Oncol | 2020 |
| 32679108 | Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. | Cancer Cell | 2020 |
| 33015525 | Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. | JCO Precis Oncol | 2020 |
| 32694156 | A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. | Clin Cancer Res | 2020 |
| 32355025 | Regenerative potential of prostate luminal cells revealed by single-cell analysis. | Science | 2020 |
| 32376773 | Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis. | Cancer Discov | 2020 |
| 32317181 | Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. | Eur Urol | 2020 |
| 32220891 | Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. | Clin Cancer Res | 2020 |
| 30589920 | Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. | JAMA Oncol | 2019 |
| 31768066 | High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. | Nat Med | 2019 |
| 31204311 | Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. | Eur Urol Oncol | 2019 |
| 31152158 | Publisher Correction: The long tail of oncogenic drivers in prostate cancer. | Nat Genet | 2019 |
| 31061129 | Genomic correlates of clinical outcome in advanced prostate cancer. | Proc Natl Acad Sci U S A | 2019 |
| 30602500 | Low Expression of the Androgen-Induced Tumor Suppressor Gene <i>PLZF</i> and Lethal Prostate Cancer. | Cancer Epidemiol Biomarkers Prev | 2019 |
| 29236593 | Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. | J Clin Oncol | 2018 |